Please login to the form below

Not currently logged in
Email:
Password:

Alnylam teams with Isis on joint startup

Alnylam forms jv company with Isis to commercialise microRNA-derived (miRN) drugs in the US

US-based Alnylam Pharmaceuticals has formed a joint venture (jv) company, Regulus Therapeutics, with Isis Pharmaceuticals to commercialise microRNA-derived (miRN) drugs in the US.

Regulus will combine technologies from Alnylam and Isis Pharmaceuticals to create the jv, which will be controlled by a separate management team, board of directors and scientific advisory board. The new firm will be chaired by Nobel prize winner, David Baltimore.

Alnylam added that the company will make an initial investment of USD 10m in Regulus, and will share future funding of the venture with Isis. Both Alnylam and Isis have granted the new company exclusive licenses to miRNA technology of Isis and Alnylam.

MiRN drugs are expected to be able to regulate multiple human genes with potential to treat a number of presently unmet medical needs.

Alnylam develops drugs which implement RNA-interference (RNAi) technology that works by switching off damaged or lethal genes thereby treating diseases. Alnylam reported a FY06 net loss of USD 34.6m on sales of USD 26.9m.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics